索托拉西布治疗KRAS G12C突变非小细胞肺癌:德国同情用药项目多中心真实世界经验
该多中心真实世界分析纳入2020至2022年德国同情用药项目中163例接受索托拉西布治疗的KRAS p.G12C突变晚期或转移性非小细胞肺癌患者,客观缓解率为38.7%,中位总生存期为9.8个月(95%CI 6.5至未达到),中位真实世界无进展生存期为4.8个月(9%CI 3.9至5.9)。合并KEAP1突变似乎与更差生存相关,PD-L1表达似乎影响疗效。
要点
- 客观缓解率为38.7%,中位总生存期为9.8个月(95%CI 6.5至未达到)。
- 合并KEAP1突变似乎与更差生存相关,脑转移、STK11和TP53突变对疗效和生存无影响。
- 剂量减量和永久停药分别发生于35例(21.5%)和7例(4.3%)患者。
核心结论
- 真实世界人群的初步结果证实索托拉西布治疗晚期KRAS p.G12C突变非小细胞肺癌具有 promising 疗效。
- 合并KEAP1突变的患者似乎获益较少。
研究设计与样本
- 德国多中心索托拉西布同情用药项目,纳入2020至2022年接受索托拉西布治疗的KRAS p.G12C突变晚期或转移性非小细胞肺癌患者。
- 共分析163例患者,既往中位治疗线数为2线(范围0至7)。
- 分析全队列及特殊关注亚组(如合并突变和不同PD-L1表达水平)的疗效、耐受性和生存。
主要发现
- 每4例患者中1例体力状态较差,38%有脑转移。
- 客观缓解率为38.7%。
- 中位总生存期为9.8个月(95%CI 6.5至未达到)。
- 中位真实世界无进展生存期为4.8个月(9%CI 3.9至5.9)。
- 剂量减量和永久停药分别发生于35例(21.5%)和7例(4.3%)患者。
关键数值与推荐
- 客观缓解率为38.7%。
- 中位总生存期为9.8个月(95%CI 6.5至未达到)。
- 中位真实世界无进展生存期为4.8个月(9%CI 3.9至5.9)。
- 剂量减量35例(21.5%),永久停药7例(4.3%)。
- 每4例患者中1例体力状态较差,38%有脑转移。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sotorasib is a first-in-class KRAS p.G12C-inhibitor that has entered clinical trials in pretreated patients with non-small cell lung cancer (NSCLC) in 2018. First response rates were promising in the CodeBreaK trials. It remains unclear whether response to sotorasib and outcomes differ in a real-world setting when including patients underrepresented in clinical trials. METHODS: Patients with KRAS p.G12C-mutated advanced or metastatic NSCLC received sotorasib within the German multicenter sotorasib compassionate use program between 2020 to 2022. Data on efficacy, tolerability, and survival were analyzed in the full cohort and in subgroups of special interest such as co-occurring mutations and across PD-L1 expression levels. RESULTS: We analyzed 163 patients who received sotorasib after a median of two treatment lines (range, 0 to 7). Every fourth patient had a poor performance status and 38% had brain metastases (BM). The objective response rate was 38.7%. The median overall survival was 9.8 months (95% CI, 6.5 to not reached). Median real-world (rw) progression-free survival was 4.8 months (9% CI, 3.9 to 5.9). Dose reductions and permanent discontinuation were necessary in 35 (21.5%) and 7 (4.3%) patients, respectively. Efficacy seems to be influenced by PD-L1 expression and a co-occurring KEAP1 mutation. KEAP1 was associated with an inferior survival. Other factors such as BM, STK11, and TP53 mutations had no impact on response and survival. CONCLUSION: First results from a real-world population confirm promising efficacy of sotorasib for the treatment of advanced KRAS p.G12C-mutated NSCLC. Patients with co-occurring KEAP1 mutations seem to derive less benefit.
引用
- Stratmann JA, Althoff FC, Doebel P, et al. Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany. Eur J Cancer. 2024. PMID: 38377774. doi:10.1016/j.ejca.2024.113911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。